KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Deferred Taxes (2021 - 2025)

Historic Deferred Taxes for Pacific Biosciences Of California (PACB) over the last 4 years, with Q1 2025 value amounting to -$546000.0.

  • Pacific Biosciences Of California's Deferred Taxes changed N/A to -$546000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was -$751000.0, marking a year-over-year decrease of 459.61%. This contributed to the annual value of -$205000.0 for FY2024, which is 9820.55% up from last year.
  • As of Q1 2025, Pacific Biosciences Of California's Deferred Taxes stood at -$546000.0.
  • Pacific Biosciences Of California's Deferred Taxes' 5-year high stood at $1.2 million during Q4 2021, with a 5-year trough of -$718000.0 in Q4 2023.
  • Over the past 4 years, Pacific Biosciences Of California's median Deferred Taxes value was -$375500.0 (recorded in 2024), while the average stood at -$73500.0.
  • Data for Pacific Biosciences Of California's Deferred Taxes shows a peak YoY increase of 7144.85% (in 2024) and a maximum YoY decrease of 7144.85% (in 2024) over the last 5 years.
  • Pacific Biosciences Of California's Deferred Taxes (Quarter) stood at $1.2 million in 2021, then crashed by 161.11% to -$718000.0 in 2023, then skyrocketed by 71.45% to -$205000.0 in 2024, then tumbled by 166.34% to -$546000.0 in 2025.
  • Its Deferred Taxes was -$546000.0 in Q1 2025, compared to -$205000.0 in Q4 2024 and -$718000.0 in Q4 2023.